

As Passed by the Senate

136th General Assembly

Regular Session

2025-2026

Sub. S. B. No. 230

Senator Romanchuk

**Cosponsors: Senators Liston, Ingram, Antonio, Cirino, Craig, Hicks-Hudson,
Reineke, Roegner**

To amend sections 1751.91, 3923.89, 4729.01, 1
5164.14, and 5167.051 and to enact sections 2
4729.392 and 4729.393 of the Revised Code to 3
authorize pharmacists to screen, test, and 4
provide treatment for certain respiratory health 5
conditions. 6

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That sections 1751.91, 3923.89, 4729.01, 7
5164.14, and 5167.051 be amended and sections 4729.392 and 8
4729.393 of the Revised Code be enacted to read as follows: 9

Sec. 1751.91. ~~A~~-(A) Notwithstanding section 3901.71 of the 10
Revised Code, a health insuring corporation ~~may~~ shall provide 11
payment or reimbursement to a pharmacist for providing a health 12
care service to a patient ~~if both of the following are the case:~~ 13

~~(A) The pharmacist provided the health care service to the~~ 14
~~patient in accordance with,~~ in the same manner that it provides 15
payment or reimbursement to any other health care provider for 16
providing a health care service that is the equivalent of the 17
pharmacist-provided health care service, as long as the 18
patient's individual or group health insuring corporation 19

policy, contract, or agreement includes coverage of that type of 20
health care service. 21

(B) Division (A) of this section applies in the case of 22
any health care service that a pharmacist is authorized by 23
Chapter 4729. of the Revised Code to provide, including any of 24
the following ~~services:~~ 25

(1) Managing drug therapy under a consult agreement 26
pursuant to section 4729.39 of the Revised Code; 27

(2) Conducting screenings, ordering and administering 28
laboratory and diagnostic tests, evaluating the results of such 29
screenings and tests, and treating health conditions, to the 30
extent that the foregoing activities are authorized by section 31
4729.392 of the Revised Code; 32

~~(3) Administering immunizations in accordance with~~ 33
~~pursuant to section 4729.41 of the Revised Code;~~ 34

~~(3)-(4) Administering drugs in accordance with by~~ 35
~~injection pursuant to section 4729.45 of the Revised Code.~~ 36

~~(B) The patient's individual or group health insuring~~ 37
~~corporation policy, contract, or agreement provides for payment~~ 38
~~or reimbursement of the service.~~ 39

Sec. 3923.89. ~~A-~~(A) Notwithstanding section 3901.71 of the 40
Revised Code, a sickness and accident insurer or public employee 41
benefit plan may shall provide payment or reimbursement to a 42
pharmacist for providing a health care service to a patient-if- 43
both of the following are the case: 44

~~(A) The pharmacist provided the health care service to the~~ 45
~~patient in accordance with,~~ in the same manner that it provides 46
payment or reimbursement to any other health care provider for 47

providing a health care service that is the equivalent of the 48
pharmacist-provided health care service, as long as the 49
patient's individual or group sickness and accident insurance 50
policy or public employee benefit plan includes coverage of that 51
type of health care service. 52

(B) Division (A) of this section applies in the case of 53
any health care service that a pharmacist is authorized by 54
Chapter 4729. of the Revised Code to provide, including any of 55
the following ~~services:~~ 56

(1) Managing drug therapy under a consult agreement 57
pursuant to section 4729.39 of the Revised Code; 58

(2) Conducting screenings, ordering and administering 59
laboratory and diagnostic tests, evaluating the results of such 60
screenings and tests, and treating health conditions, to the 61
extent that the foregoing activities are authorized by section 62
4729.392 of the Revised Code; 63

(3) Administering immunizations in accordance with 64
pursuant to section 4729.41 of the Revised Code; 65

~~(3)~~ (4) Administering drugs in accordance with by 66
injection pursuant to section 4729.45 of the Revised Code. 67

~~(B) The patient's individual or group policy of sickness~~ 68
~~and accident insurance or public employee benefit plan provides~~ 69
~~for payment or reimbursement of the service.~~ 70

Sec. 4729.01. As used in this chapter: 71

(A) "Pharmacy," except when used in a context that refers 72
to the practice of pharmacy, means any area, room, rooms, place 73
of business, department, or portion of any of the foregoing 74
where the practice of pharmacy is conducted. 75

(B) "Practice of pharmacy" means providing pharmacist care	76
requiring specialized knowledge, judgment, and skill derived	77
from the principles of biological, chemical, behavioral, social,	78
pharmaceutical, and clinical sciences. As used in this division,	79
"pharmacist care" includes the following:	80
(1) Interpreting prescriptions;	81
(2) Dispensing drugs and drug therapy related devices;	82
(3) Compounding drugs;	83
(4) Counseling individuals with regard to their drug	84
therapy, recommending drug therapy related devices, and	85
assisting in the selection of drugs and appliances for treatment	86
of common diseases and injuries and providing instruction in the	87
proper use of the drugs and appliances;	88
(5) Performing drug regimen reviews with individuals by	89
discussing all of the drugs that the individual is taking and	90
explaining the interactions of the drugs;	91
(6) Performing drug utilization reviews with licensed	92
health professionals authorized to prescribe drugs when the	93
pharmacist determines that an individual with a prescription has	94
a drug regimen that warrants additional discussion with the	95
prescriber;	96
(7) Advising an individual and the health care	97
professionals treating an individual with regard to the	98
individual's drug therapy;	99
(8) Acting pursuant to a consult agreement, if an	100
agreement has been established;	101
(9) <u>Conducting screenings, ordering and administering</u>	102
<u>laboratory and diagnostic tests, evaluating the results of such</u>	103

screenings and tests, and treating health conditions, to the 104
extent that the foregoing activities are authorized by section 105
4729.392 of the Revised Code; 106

(10) Engaging in the administration of immunizations to 107
the extent authorized by section 4729.41 of the Revised Code; 108

~~(10)~~ (11) Engaging in the administration by injection of 109
drugs, to the extent authorized by section 4729.45 of the 110
Revised Code. 111

(C) "Compounding" means the preparation, mixing, 112
assembling, packaging, and labeling of one or more drugs in any 113
of the following circumstances: 114

(1) Pursuant to a prescription issued by a licensed health 115
professional authorized to prescribe drugs; 116

(2) Pursuant to the modification of a prescription made in 117
accordance with a consult agreement; 118

(3) As an incident to research, teaching activities, or 119
chemical analysis; 120

(4) In anticipation of orders for drugs pursuant to 121
prescriptions, based on routine, regularly observed dispensing 122
patterns; 123

(5) Pursuant to a request made by a licensed health 124
professional authorized to prescribe drugs for a drug that is to 125
be used by the professional for the purpose of direct 126
administration to patients in the course of the professional's 127
practice, if all of the following apply: 128

(a) At the time the request is made, the drug is not 129
commercially available regardless of the reason that the drug is 130
not available, including the absence of a manufacturer for the 131

drug or the lack of a readily available supply of the drug from	132
a manufacturer.	133
(b) A limited quantity of the drug is compounded and	134
provided to the professional.	135
(c) The drug is compounded and provided to the	136
professional as an occasional exception to the normal practice	137
of dispensing drugs pursuant to patient-specific prescriptions.	138
(D) "Consult agreement" means an agreement that has been	139
entered into under section 4729.39 of the Revised Code.	140
(E) "Drug" means:	141
(1) Any article recognized in the United States	142
pharmacopoeia and national formulary, or any supplement to them,	143
intended for use in the diagnosis, cure, mitigation, treatment,	144
or prevention of disease in humans or animals;	145
(2) Any other article intended for use in the diagnosis,	146
cure, mitigation, treatment, or prevention of disease in humans	147
or animals;	148
(3) Any article, other than food, intended to affect the	149
structure or any function of the body of humans or animals;	150
(4) Any article intended for use as a component of any	151
article specified in division (E) (1), (2), or (3) of this	152
section; but does not include devices or their components,	153
parts, or accessories.	154
"Drug" does not include "hemp" as that term is defined in	155
section 928.01 of the Revised Code.	156
(F) "Dangerous drug" means any of the following:	157
(1) Any drug to which either of the following applies:	158

(a) Under the "Federal Food, Drug, and Cosmetic Act," 52	159
Stat. 1040 (1938), 21 U.S.C.A. 301, as amended, the drug is	160
required to bear a label containing the legend "Caution: Federal	161
law prohibits dispensing without prescription" or "Caution:	162
Federal law restricts this drug to use by or on the order of a	163
licensed veterinarian" or any similar restrictive statement, or	164
the drug may be dispensed only upon a prescription;	165
(b) Under Chapter 3715. or 3719. of the Revised Code, the	166
drug may be dispensed only upon a prescription.	167
(2) Any drug that contains a schedule V controlled	168
substance and that is exempt from Chapter 3719. of the Revised	169
Code or to which that chapter does not apply;	170
(3) Any drug intended for administration by injection into	171
the human body other than through a natural orifice of the human	172
body;	173
(4) Any drug that is a biological product, as defined in	174
section 3715.01 of the Revised Code.	175
(G) "Federal drug abuse control laws" has the same meaning	176
as in section 3719.01 of the Revised Code.	177
(H) "Prescription" means all of the following:	178
(1) A written, electronic, or oral order for drugs or	179
combinations or mixtures of drugs to be used by a particular	180
individual or for treating a particular animal, issued by a	181
licensed health professional authorized to prescribe drugs;	182
(2) For purposes of sections 4723.4810, 4729.282,	183
4730.432, and 4731.93 of the Revised Code, a written,	184
electronic, or oral order for a drug to treat chlamydia,	185
gonorrhea, or trichomoniasis issued to and in the name of a	186

patient who is not the intended user of the drug but is the	187
sexual partner of the intended user;	188
(3) For purposes of sections 3313.7110, 3313.7111,	189
3314.143, 3326.28, 3328.29, 4723.483, 4729.88, 4730.433,	190
4731.96, and 5180.26 of the Revised Code, a written, electronic,	191
or oral order for an epinephrine autoinjector issued to and in	192
the name of a school, school district, or camp;	193
(4) For purposes of Chapter 3728. and sections 4723.483,	194
4729.88, 4730.433, and 4731.96 of the Revised Code, a written,	195
electronic, or oral order for an epinephrine autoinjector issued	196
to and in the name of a qualified entity, as defined in section	197
3728.01 of the Revised Code;	198
(5) For purposes of sections 3313.7115, 3313.7116,	199
3314.147, 3326.60, 3328.38, 4723.4811, 4730.437, 4731.92, and	200
5180.262 of the Revised Code, a written, electronic, or oral	201
order for injectable or nasally administered glucagon in the	202
name of a school, school district, or camp.	203
(I) "Licensed health professional authorized to prescribe	204
drugs" or "prescriber" means an individual who is authorized by	205
law to prescribe drugs or dangerous drugs or drug therapy	206
related devices in the course of the individual's professional	207
practice, including only the following:	208
(1) A dentist licensed under Chapter 4715. of the Revised	209
Code;	210
(2) A clinical nurse specialist, certified nurse-midwife,	211
or certified nurse practitioner who holds a current, valid	212
license issued under Chapter 4723. of the Revised Code to	213
practice nursing as an advanced practice registered nurse;	214
(3) A certified registered nurse anesthetist who holds a	215

current, valid license issued under Chapter 4723. of the Revised	216
Code to practice nursing as an advanced practice registered	217
nurse, but only to the extent of the nurse's authority under	218
section 4723.43 of the Revised Code;	219
(4) An optometrist licensed under Chapter 4725. of the	220
Revised Code to practice optometry;	221
(5) A physician authorized under Chapter 4731. of the	222
Revised Code to practice medicine and surgery, osteopathic	223
medicine and surgery, or podiatric medicine and surgery;	224
(6) A physician assistant who holds a license to practice	225
as a physician assistant issued under Chapter 4730. of the	226
Revised Code, holds a valid prescriber number issued by the	227
state medical board, and has been granted physician-delegated	228
prescriptive authority;	229
(7) A veterinarian licensed under Chapter 4741. of the	230
Revised Code;	231
(8) A certified mental health assistant licensed under	232
Chapter 4772. of the Revised Code who has been granted	233
physician-delegated prescriptive authority by the physician	234
supervising the certified mental health assistant.	235
(J) "Sale" or "sell" includes any transaction made by any	236
person, whether as principal proprietor, agent, or employee, to	237
do or offer to do any of the following: deliver, distribute,	238
broker, exchange, gift or otherwise give away, or transfer,	239
whether the transfer is by passage of title, physical movement,	240
or both.	241
(K) "Wholesale sale" and "sale at wholesale" mean any sale	242
in which the purpose of the purchaser is to resell the article	243
purchased or received by the purchaser.	244

(L) "Retail sale" and "sale at retail" mean any sale other than a wholesale sale or sale at wholesale.	245 246
(M) "Retail seller" means any person that sells any dangerous drug to consumers without assuming control over and responsibility for its administration. Mere advice or instructions regarding administration do not constitute control or establish responsibility.	247 248 249 250 251
(N) "Price information" means the price charged for a prescription for a particular drug product and, in an easily understandable manner, all of the following:	252 253 254
(1) The proprietary name of the drug product;	255
(2) The established (generic) name of the drug product;	256
(3) The strength of the drug product if the product contains a single active ingredient or if the drug product contains more than one active ingredient and a relevant strength can be associated with the product without indicating each active ingredient. The established name and quantity of each active ingredient are required if such a relevant strength cannot be so associated with a drug product containing more than one ingredient.	257 258 259 260 261 262 263 264
(4) The dosage form;	265
(5) The price charged for a specific quantity of the drug product. The stated price shall include all charges to the consumer, including, but not limited to, the cost of the drug product, professional fees, handling fees, if any, and a statement identifying professional services routinely furnished by the pharmacy. Any mailing fees and delivery fees may be stated separately without repetition. The information shall not be false or misleading.	266 267 268 269 270 271 272 273

(O) "Wholesale distributor of dangerous drugs" or 274
"wholesale distributor" means a person engaged in the sale of 275
dangerous drugs at wholesale and includes any agent or employee 276
of such a person authorized by the person to engage in the sale 277
of dangerous drugs at wholesale. 278

(P) "Manufacturer of dangerous drugs" or "manufacturer" 279
means a person, other than a pharmacist or prescriber, who 280
manufactures dangerous drugs and who is engaged in the sale of 281
those dangerous drugs. 282

(Q) "Terminal distributor of dangerous drugs" or "terminal 283
distributor" means a person who is engaged in the sale of 284
dangerous drugs at retail, or any person, other than a 285
manufacturer, repackager, outsourcing facility, third-party 286
logistics provider, wholesale distributor, or pharmacist, who 287
has possession, custody, or control of dangerous drugs for any 288
purpose other than for that person's own use and consumption. 289
"Terminal distributor" includes pharmacies, hospitals, nursing 290
homes, and laboratories and all other persons who procure 291
dangerous drugs for sale or other distribution by or under the 292
supervision of a pharmacist, licensed health professional 293
authorized to prescribe drugs, or other person authorized by the 294
state board of pharmacy. 295

(R) "Promote to the public" means disseminating a 296
representation to the public in any manner or by any means, 297
other than by labeling, for the purpose of inducing, or that is 298
likely to induce, directly or indirectly, the purchase of a 299
dangerous drug at retail. 300

(S) "Person" includes any individual, partnership, 301
association, limited liability company, or corporation, the 302
state, any political subdivision of the state, and any district, 303

department, or agency of the state or its political 304
subdivisions. 305

(T) (1) "Animal shelter" means a facility operated by a 306
humane society or any society organized under Chapter 1717. of 307
the Revised Code or a dog pound operated pursuant to Chapter 308
955. of the Revised Code. 309

(2) "County dog warden" means a dog warden or deputy dog 310
warden appointed or employed under section 955.12 of the Revised 311
Code. 312

(3) "Wild animal rehabilitation facility" means a facility 313
that holds a permit issued by the chief of the division of 314
wildlife for rehabilitation purposes in accordance with section 315
1533.08 of the Revised Code or rules adopted by the chief. 316

(U) "Food" has the same meaning as in section 3715.01 of 317
the Revised Code. 318

(V) "Pain management clinic" has the same meaning as in 319
section 4731.054 of the Revised Code. 320

(W) "Investigational drug or product" means a drug or 321
product that has successfully completed phase one of the United 322
States food and drug administration clinical trials and remains 323
under clinical trial, but has not been approved for general use 324
by the United States food and drug administration. 325

"Investigational drug or product" does not include controlled 326
substances in schedule I, as defined in section 3719.01 of the 327
Revised Code. 328

(X) "Product," when used in reference to an 329
investigational drug or product, means a biological product, 330
other than a drug, that is made from a natural human, animal, or 331
microorganism source and is intended to treat a disease or 332

medical condition. 333

(Y) "Third-party logistics provider" means a person that 334
provides or coordinates warehousing or other logistics services 335
pertaining to dangerous drugs including distribution, on behalf 336
of a manufacturer, wholesale distributor, or terminal 337
distributor of dangerous drugs, but does not take ownership of 338
the drugs or have responsibility to direct the sale or 339
disposition of the drugs. 340

(Z) "Repackager of dangerous drugs" or "repackager" means 341
a person that repacks and relabels dangerous drugs for sale or 342
distribution. 343

(AA) "Outsourcing facility" means a facility that is 344
engaged in the compounding and sale of sterile drugs and is 345
registered as an outsourcing facility with the United States 346
food and drug administration. 347

(BB) "Laboratory" means a laboratory licensed under this 348
chapter as a terminal distributor of dangerous drugs and 349
entrusted to have custody of any of the following drugs and to 350
use the drugs for scientific and clinical purposes and for 351
purposes of instruction: dangerous drugs that are not controlled 352
substances, as defined in section 3719.01 of the Revised Code; 353
dangerous drugs that are controlled substances, as defined in 354
that section; and controlled substances in schedule I, as 355
defined in that section. 356

(CC) "Overdose reversal drug" means both of the following: 357

(1) Naloxone; 358

(2) Any other drug that the state board of pharmacy, 359
through rules adopted in accordance with Chapter 119. of the 360
Revised Code, designates as a drug that is approved by the 361

federal food and drug administration for the reversal of a known 362
or suspected opioid-related overdose. 363

Sec. 4729.392. (A) Pursuant to the statewide written 364
protocol developed by the state board of pharmacy under section 365
4729.393 of the Revised Code, a pharmacist may conduct 366
screenings, order and administer laboratory and diagnostic 367
tests, evaluate the results of the screenings conducted and 368
tests that are ordered and administered, and provide treatment 369
to an individual who is five years of age or older for the 370
following health conditions: 371

(1) Influenza; 372

(2) Pharyngitis caused by the bacteria known as "group A 373
Streptococcus"; 374

(3) COVID-19. 375

(B) All of the following apply with respect to a 376
pharmacist's authority established by this section to conduct 377
screenings and to order and administer laboratory and diagnostic 378
tests: 379

(1) A pharmacist may use any established procedures that 380
can safely be performed by a pharmacist. 381

(2) A pharmacist may use any tests to guide diagnosis or 382
clinical decision-making that qualify for a waiver under the 383
"Clinical Laboratory Improvement Amendments of 1988," 42 U.S.C. 384
263a, or the federal regulations adopted thereunder, as 385
determined by the United States centers for medicare and 386
medicaid services. 387

(3) Notwithstanding any provision of the Revised Code to 388
the contrary, a pharmacist may delegate technical and 389

administrative tasks associated with screening and testing to a 390
pharmacy intern, registered pharmacy technician, or certified 391
pharmacy technician, as long as the person to whom the tasks are 392
delegated is acting under the direct supervision of the 393
pharmacist. 394

(C) As part of a pharmacist's authority established by 395
this section to provide treatment, a pharmacist may initiate 396
drug therapy, notwithstanding the definition of "licensed health 397
professional authorized to prescribe drugs" in section 4729.01 398
of the Revised Code. 399

(D) The state board of pharmacy may adopt rules as it 400
considers necessary to implement this section. Any rules adopted 401
under this division shall be adopted in accordance with Chapter 402
119. of the Revised Code. 403

(E) This section is an alternative to the authority 404
granted by sections 4729.39 and 4729.42 of the Revised Code. 405

Sec. 4729.393. (A) The state board of pharmacy shall 406
develop a statewide written protocol for pharmacists to use when 407
conducting screenings, ordering and administering laboratory and 408
diagnostic tests, evaluating the results of the screenings 409
conducted and tests that are ordered and administered, and 410
providing treatment for health conditions pursuant to section 411
4729.392 of the Revised Code. The protocol shall include all of 412
the following: 413

(1) Specific categories of patients a pharmacist is 414
authorized to test or screen; 415

(2) Instructions for obtaining relevant patient medical 416
history information to identify disqualifying health conditions, 417
adverse reactions, and contraindications to a treatment; 418

(3) Instructions for treatment based on a patient's age, symptoms, and test and screening results, including negative results; 419
420
421

(4) Requirements for notifying a patient's primary care provider of the tests and screenings ordered or performed and the treatment provided; 422
423
424

(5) Clinical criteria requiring referral to a physician or other health care provider; 425
426

(6) Dangerous drugs authorized as the approved course of treatment for specific conditions; 427
428

(7) Any other provisions that the board considers appropriate. 429
430

(B) All of the following procedures apply to the development of a protocol under this section: 431
432

(1) Before the protocol is finalized, the state board of pharmacy shall submit a draft protocol to the state medical board for review. 433
434
435

(2) During the sixty-day period immediately following receipt of the draft protocol, the state medical board may submit comments to the state board of pharmacy. Any comments from the state medical board shall be submitted in writing. 436
437
438
439

(3) If no comments are submitted by the state medical board, the state board of pharmacy shall proceed with finalizing the protocol. 440
441
442

(4) If comments are submitted by the state medical board, the state board of pharmacy shall review the comments. If it determines that revisions will not be made to incorporate or otherwise address the comments, the state board of pharmacy 443
444
445
446

shall submit to the state medial board an explanation of the 447
reasons for not making the revisions. Thereafter, the state 448
board of pharmacy shall proceed with finalizing the protocol. 449

(5) To finalize the protocol, a copy shall be delivered to 450
the president of the state board of pharmacy for the president's 451
signature. Once the president has signed the protocol, the 452
protocol is finalized and remains in effect until any revisions 453
are made under division (C) of this section. 454

(C) The state board of pharmacy shall review the protocol 455
every two years and shall make revisions as the board considers 456
necessary. If the board considers revisions to be necessary, the 457
board shall make the revisions by following the same procedures 458
that are described in division (B) of this section for 459
developing the protocol. 460

(D) The state board of pharmacy, through electronic 461
communication, shall inform all individuals licensed by the 462
board when the initial protocol and any revised protocol are 463
finalized. The board shall maintain on its internet web site a 464
copy of the version of the protocol that is in effect. 465

(E) The state board of pharmacy and state medical board 466
are not liable in damages in a civil action for injury, death, 467
or loss to person or property allegedly arising from the use of 468
the protocol, unless an act or omission by the applicable board 469
in developing, commenting on, revising, or finalizing the 470
protocol constitutes willful or wanton misconduct. 471

Sec. 5164.14. (A) The medicaid program may cover a health- 472
care service that shall provide payment to a pharmacist provides 473
to for providing a health care service to a medicaid recipient- 474
in accordance with-, in the same manner that it provides payment 475

to any other health care provider for providing a health care 476
service that is the equivalent of the pharmacist-provided health 477
care service, as long as the medicaid program covers that type 478
of health care service. 479

(B) Division (A) of this section applies in the case of 480
any health care service that a pharmacist is authorized by 481
Chapter 4729. of the Revised Code to provide, including any of 482
the following ~~services:~~ 483

~~(A)~~ (1) Managing drug therapy under a consult agreement 484
pursuant to section 4729.39 of the Revised Code; 485

~~(B)~~ (2) Conducting screenings, ordering and administering 486
laboratory and diagnostic tests, evaluating the results of such 487
screenings and tests, and treating health conditions, to the 488
extent that the foregoing activities are authorized by section 489
4729.392 of the Revised Code; 490

(3) Administering immunizations in accordance with 491
pursuant to section 4729.41 of the Revised Code; 492

~~(C)~~ (4) Administering drugs in accordance with by 493
injection pursuant to section 4729.45 of the Revised Code. 494

Sec. 5167.051. ~~If the medicaid program covers the~~ 495
~~pharmacist services described in~~ Under the care management 496
system, payments to a pharmacist for providing a health care 497
service are subject to the same requirements that apply to 498
medicaid payments under section 5164.14 of the Revised Code, ~~the~~ 499
~~department of medicaid may include the services in the care-~~ 500
~~management system.~~ 501

Section 2. That existing sections 1751.91, 3923.89, 502
4729.01, 5164.14, and 5167.051 of the Revised Code are hereby 503
repealed. 504

Section 3. Sections 1751.91 and 3923.89 of the Revised Code, as amended by this act, apply to contracts, policies, agreements, and plans that are delivered, issued for delivery, modified, or renewed on or after the effective date of this section.

Section 4. Section 4729.01 of the Revised Code is presented in this act as a composite of the section as amended by H.B. 52, H.B. 96, S.B. 56, and S.B. 152, all of the 136th General Assembly. The General Assembly, applying the principle stated in division (B) of section 1.52 of the Revised Code that amendments are to be harmonized if reasonably capable of simultaneous operation, finds that the composite is the resulting version of the section in effect prior to the effective date of the section as presented in this act.